The Moreau Strain of Bacillus Calmette-Guerin (BCG) for High-Risk Non-Muscle Invasive Bladder Cancer: An Alternative during Worldwide BCG Shortage?
| Autor: | Tobias Klatte, Daher C. Chade, Alvaro S. Sarkis, Leopoldo A. Ribeiro-Filho, Shahrokh F. Shariat, Willian Nahas, Sebastian L. Hofbauer |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
Oncology medicine.medical_specialty Urology medicine.medical_treatment Economic shortage Strain (injury) Disease-Free Survival Drug Administration Schedule Health Services Accessibility Internal medicine Humans Medicine Neoplasm Invasiveness Aged Retrospective Studies Bacillus (shape) Chemotherapy Bladder cancer biology Drug Substitution business.industry Middle Aged biology.organism_classification medicine.disease Combined Modality Therapy Administration Intravesical Treatment Outcome Urinary Bladder Neoplasms Chemotherapy Adjuvant Immunology BCG Vaccine Disease Progression Female Neoplasm Recurrence Local business Non muscle invasive Adjuvant BCG vaccine |
| Zdroj: | Urologia Internationalis. 96:46-50 |
| ISSN: | 1423-0399 0042-1138 |
| DOI: | 10.1159/000440701 |
| Popis: | Background: Bacillus Calmette-Guerin (BCG) is the standard of care for adjuvant intravesical instillation therapy for intermediate- and high-risk non-muscle invasive bladder cancer (NMIBC) after complete transurethral resection. Increasing evidence suggests that there are marked differences in outcomes according to BCG substrains. BCG-Moreau was recently introduced to the European market to cover the issue of BCG shortage, but there are little data regarding the oncologic efficacy. Methods: We retrospectively analyzed 295 consecutive patients, who received adjuvant intravesical instillation therapy with BCG-Moreau for intermediate- and high-risk NMIBC between October 2007 and April 2013 at a single institution. The end points of this study were time to first recurrence and progression to muscle-invasive disease. Results: Median age was 66 years (interquartile range 59-74, mean 65.9 years). According to the EAU risk group, 76 patients presented with intermediate-risk and 219 patients with high-risk NMIBC. The 5-year recurrence-free survival and progression-free survival rate was 64.8% (95% CI 52.8-74.4) and 81.4% (95% CI 65.2-90.2), respectively. Conclusions: BCG-Moreau is an effective substrain for adjuvant instillation therapies of NMIBC, and outcomes appear to be comparable to series using other substrains. During worldwide shortage of BCG-TICE, Connaught and RIVM, BCG-Moreau may serve as an equally effective alternative. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|